Analysts size retatrutide at up to $30 billion by 2031 ahead of a Q1 2027 filing

Financial analysts have circulated new projections estimating that retatrutide, an experimental weight-loss and diabetes drug from Eli Lilly, could bring in about $30 billion in annual revenue by 2031. Roughly $10 billion of that is expected to come from obesity treatment and $20 billion from diabetes care, according to Clarivate figures cited in September coverage.^[1] The company has said it plans to file a Biologics License Application with the FDA in the first quarter of 2027, with a possible 2028 launch.^[1]

Retatrutide is a triple-hormone drug that targets the GIP, GLP-1, and glucagon receptors, one more pathway than tirzepatide, the molecule sold as Mounjaro and Zepbound. In its Phase 3 program, people taking the 12 mg dose lost an average of 70.3 pounds, or 28.3% of body weight, over 80 weeks.^[1] That is not yet an FDA-reviewed approval, and the drug has not been submitted for review.

The same analysis projected that orforglipron, Lilly's oral GLP-1 pill sold as Foundayo, could reach about $16 billion in sales by 2031.^[1] Foundayo is already approved and generated $98 million in its first reported quarter on the market.^[1] For comparison, Lilly's existing tirzepatide products brought in $15.7 billion in the second quarter of 2026 alone, with Zepbound sales up 46% and Mounjaro sales up 91% year over year.^[1]

To prepare for this growth, Lilly has been spending heavily on manufacturing. The company's capital expenditure reached $9.9 billion over the trailing twelve months, largely tied to new production capacity.^[1] A separate analysis noted Lilly has committed tens of billions of dollars to new plants in the United States and Europe, built years ahead of the demand the company expects.^[2] That same analysis also noted that Wall Street's overall estimate for the global obesity drug market by 2030 has climbed over time, from around $50 billion a few years ago to a current midpoint near $130 billion, with some forecasts as high as $150 billion.^[2]

Why it matters for patients

These are financial projections, not medical facts, and they say nothing about whether retatrutide will be approved or how it will compare to other GLP-1 drugs once it reaches pharmacies. The BLA filing planned for the first quarter of 2027 is a regulatory step, not a guarantee of approval, and the FDA could ask for more data or reject the application. If retatrutide is cleared and launched around 2028 as projected, patients could eventually have another option beyond semaglutide and tirzepatide, potentially with different weight-loss results, side effects, or insurance coverage terms. Manufacturing capacity has been a persistent bottleneck for GLP-1 drugs, so Lilly's spending on new plants may matter as much to patients as the drug's trial results, since supply shortages have affected access to Zepbound and Mounjaro in the past.^[1][2] For now, retatrutide is not available to patients, and the market forecasts described here reflect what investment analysts expect Lilly's business to look like, not medical guidance about the drug's safety or effectiveness.

What happens next

Lilly has said it plans to submit a Biologics License Application for retatrutide to the FDA in the first quarter of 2027.^[1] Analysts cited in the reporting expect a possible launch window in 2028 if that filing leads to approval.^[1] Until the FDA reviews the application, retatrutide's approval, timeline, and eventual labeling remain unknown. The company's continued spending on manufacturing capacity, which reached $9.9 billion in capital expenditure over the past twelve months, will also be a signal to watch, since it reflects how much supply Lilly is preparing to build out ahead of any approval.^[1]